Very good session yesterday, lots of interesting topics. The AM session was very interesting talks, especially from Dr. Lin (University of Kentucky) about caloric restriction and enhanced CBF during aging. She proposed that glucose-rich diet may contribute in decrease in CBF during aging and thus may contribute to vascular cognitive impairment. She also suggested ketogenic diet maybe an alternative to carb-rich diet to improve CBF.
It would be interesting to see how ketone bodies may affect CBF and in especially how it impacts cognitive outcome, as some patients have to be on a ketogenic diet by necessity (GLUT1 deficiency syndrome) or by medical condition (epileptic-drug resistant patients).
Another interesting talk came from Dr. Lazarov (University of Illinois-Chicago) about the importance of caveolin-1 during post-stroke neurogenesis. Interestingly enough, caveolin-1 is a protein noramally present at the BBB that may have some function on drug diffusion by receptor-mediated transcytosis or by pinocytosis. A common sense would have expected that such protein would increase during hypoxia-ischemia. Indeed it seems that is going a certain down-regulation. Furthermore, Cav-1 KO mice showed less neurogenesis at the SVZ following hypoxia. That was very interesting.
Another series of good AM talks came from Dr. Iadecola bringing more lights on a very interesting transporter recently described: Msfd2a and its contribution in hypertension-mediated BBB disruption and from Dr. Zlokovic (USC) that described the contribution of GLUT1 on Abeta metabolism and clearance at the BBB, as well as a novel of proteins involved in cell trafficking: PICALM. Finally the session closed with Dr. Edith Hamel (McGill University) on trying to rebrand two FDA-approved molecules used commonly against cholesterol (simvastatin) and hypertension (losartan) as a possible tool to improve outcomes in patients suffering from cognitive impairment due to vascular cognitive impairment and Alzheimer’s diseases.
A particular feature that I felt well designed was the Journal of Cerebral Blood Flow & Metabolism (the official journal of the society) have a highlights of the most cited papers between this conference and the previous one.
An interesting talk from Katya Park (U of Toronto) showed some interesting results of BM-derived EPCs as secreting cells capable to partially help neurons recovery from stroke injury. However these BM-derived EPCs were remotely acting and secreting their factors, whereas another kind of stem cells called Human Umbilicial Cord perivascular cells (HUCPVC) were capable to show similar results but appeared to migrate in the perivascular space of the affected region. Thats sounded very interesting and in par from what Dr. Dore-Duffy and early clinical trials using MSCs described: a selective homing in the perivascular space then secretion of survival factors from there.
Finally the session closed with Dr. Gary Rosenberg (University of New Mexico), a well-known BBB researcher about vascular cognitive impairments, biomarkers and prognosis.
He described three important points: 1) Hypertension that triggers the onset of the pathology, followed by 2) Hypoxia and the fairly sustained HIF-1alpha activation (I was curious to see whats happens to HIF-2a) and finally 3) inflammation.
The day ended with a nice Banquet on a boat that toured us through Vancouver coast line, it was some great time to meet and greet and also sparked some discussion about how the Brain and BBB people are not really matching together. Very few BBB people here but also very good sciences that can benefit BBB people either at the Gordon or at the CVB meeting. Maybe the next venue of Brain 2017 is distant enough in terms of time to have more BBB people attending and maybe from Brain people attending the CVB meeting as until now both were close in terms of time but also “pricy” in terms of venues.